
Exelixis Inc
XETRA:EX9

Intrinsic Value
The intrinsic value of one
EX9
stock under the Base Case scenario is
19.72
EUR.
Compared to the current market price of 21.09 EUR,
Exelixis Inc
is
Overvalued by 7%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Exelixis Inc
Fundamental Analysis

Exelixis remains heavily reliant on cabozantinib-based therapies for revenue, exposing it to significant downside risk if competition or unfavorable trial data diminishes demand for this cornerstone product.
Cabometyx has shown strong clinical performance in multiple indications, and its success in kidney and liver cancers could lead to expanded use cases and sustained revenue growth.

Revenue & Expenses Breakdown
Exelixis Inc
Balance Sheet Decomposition
Exelixis Inc
Current Assets | 1.5B |
Cash & Short-Term Investments | 1.1B |
Receivables | 265.4m |
Other Current Assets | 90.9m |
Non-Current Assets | 1.5B |
Long-Term Investments | 637.3m |
PP&E | 119.4m |
Intangibles | 63.7m |
Other Non-Current Assets | 659.7m |
Free Cash Flow Analysis
Exelixis Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Exelixis Inc
Revenue
|
2.2B
USD
|
Cost of Revenue
|
-76.2m
USD
|
Gross Profit
|
2.1B
USD
|
Operating Expenses
|
-1.4B
USD
|
Operating Income
|
689.9m
USD
|
Other Expenses
|
-168.7m
USD
|
Net Income
|
521.3m
USD
|
EX9 Profitability Score
Profitability Due Diligence
Exelixis Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.

Score
Exelixis Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
EX9 Solvency Score
Solvency Due Diligence
Exelixis Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

Score
Exelixis Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EX9 Price Targets Summary
Exelixis Inc
According to Wall Street analysts, the average 1-year price target for
EX9
is 21.9 EUR
with a low forecast of 13.41 EUR and a high forecast of 27.27 EUR.
Dividends
Current shareholder yield for EXEL is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
EX9
stock under the Base Case scenario is
19.72
EUR.
Compared to the current market price of 21.09 EUR,
Exelixis Inc
is
Overvalued by 7%.